146 related articles for article (PubMed ID: 36220845)
81. Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy.
Zeng M; Chen X; Song Y; Cai C
BMC Ophthalmol; 2022 Mar; 22(1):110. PubMed ID: 35260118
[TBL] [Abstract][Full Text] [Related]
82. Assessment of the efficacy of photodynamic therapy in patients with chronic central serous chorioretinopathy.
Manethová K; Ernest J; Hrevuš M; Jirásková N
Cesk Slov Oftalmol; 2020; 75(6):298-308. PubMed ID: 32911945
[TBL] [Abstract][Full Text] [Related]
83. Utility of an additional photodynamic therapy session after multiple failed PDT treatments in chronic central serous chorioretinopathy.
Moreno-Morillo FJ; Fernández-Vigo JI; Burgos-Blasco B; Moriche-Carretero M; López-Guajardo L; Donate-López J
Photodiagnosis Photodyn Ther; 2022 Sep; 39():102953. PubMed ID: 35690322
[TBL] [Abstract][Full Text] [Related]
84. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.
Kim YK; Ryoo NK; Woo SJ; Park KH
Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629
[TBL] [Abstract][Full Text] [Related]
85. Assessment of choriocapillary blood flow changes in response to half-dose photodynamic therapy in chronic central serous chorioretinopathy using optical coherence tomography angiography.
Liu J; Chen C; Li L; Xu Y; Yi Z; He L; Zheng H
BMC Ophthalmol; 2020 Oct; 20(1):402. PubMed ID: 33028272
[TBL] [Abstract][Full Text] [Related]
86. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
[TBL] [Abstract][Full Text] [Related]
87. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Kabadayi K
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
[TBL] [Abstract][Full Text] [Related]
88. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.
Koytak A; Erol K; Coskun E; Asik N; Öztürk H; Özertürk Y
Retina; 2010; 30(10):1698-703. PubMed ID: 20539254
[TBL] [Abstract][Full Text] [Related]
89. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
[TBL] [Abstract][Full Text] [Related]
90. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.
Lai TY; Chan WM; Li H; Lai RY; Liu DT; Lam DS
Br J Ophthalmol; 2006 Jul; 90(7):869-74. PubMed ID: 16597666
[TBL] [Abstract][Full Text] [Related]
91. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.
Liu HY; Yang CH; Yang CM; Ho TC; Lin CP; Hsieh YT
Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002
[TBL] [Abstract][Full Text] [Related]
92. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.
Russo A; Turano R; Morescalchi F; Gambicorti E; Cancarini A; Duse S; Costagliola C; Semeraro F
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1141-1148. PubMed ID: 28283732
[TBL] [Abstract][Full Text] [Related]
93. Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
Leys E; Tuttle S; Rasquin F; Neu F; Postelmans L
J Fr Ophtalmol; 2015 Oct; 38(8):709-16. PubMed ID: 26345542
[TBL] [Abstract][Full Text] [Related]
94. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
[TBL] [Abstract][Full Text] [Related]
95. Half-time photodynamic therapy for central serous chorioretinopathy.
Tsai MJ; Hsieh YT
Optom Vis Sci; 2014 Sep; 91(9):1140-5. PubMed ID: 25083838
[TBL] [Abstract][Full Text] [Related]
96. Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study.
Breukink MB; Mohabati D; van Dijk EH; den Hollander AI; de Jong EK; Dijkman G; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Sep; 94(6):565-72. PubMed ID: 27149889
[TBL] [Abstract][Full Text] [Related]
97. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
Retina; 2014 May; 34(5):964-70. PubMed ID: 24406387
[TBL] [Abstract][Full Text] [Related]
98. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
99. [Effect of low-dose PDT on perfusion of the choriocapillaris in cCSCR : An OCT-angiography-based study].
Reifeltshammer E; Feucht N; Lohmann CP; Maier M
Ophthalmologie; 2022 Jul; 119(7):699-704. PubMed ID: 34936026
[TBL] [Abstract][Full Text] [Related]
100. Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking.
Horiguchi E; Takeuchi J; Tomita R; Asai K; Nakano Y; Ota H; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Sci Rep; 2022 Oct; 12(1):17032. PubMed ID: 36220845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]